



ASX Announcement
16 December 2021

Top 20 Listed Option Holders

Invion Limited (ASX:IVX) (“Invion” or the “Company”) advises that a current statement setting out the names of the top 20 largest listed option holders and the percentage held by each is below.

Rank	Name	Current Balance	% Listed Options
1	CS THIRD NOMINEES PTY LIMITED <HSBC CUST NOM AU LTD 13 A/C>	28,977,273	10.17%
2	CS FOURTH NOMINEES PTY LIMITED <SETTLEMENT A/C>	23,364,306	8.20%
3	MS CHUNYAN NIU	20,727,851	7.27%
4	180 MARKETS PTY LTD	15,000,000	5.26%
5	EVOLUTION CAPITAL PTY LTD	15,000,000	5.26%
6	MR BIN LIU	11,582,415	4.06%
7	SPICEME CAPITAL PTY LTD	10,750,000	3.77%
8	MR MATTHEW QI	5,644,352	1.98%
9	ORCA CAPITAL GMBH	5,625,000	1.97%
10	MATTHEW BURFORD SUPER FUND PTY LTD	5,618,529	1.97%
11	DRH SUPERANNUATION PTY LTD	5,113,637	1.79%
12	MORSEC NOMINEES PTY LTD	4,745,686	1.67%
13	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED – A/C 2	4,261,364	1.50%
14	ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD <CUSTODIAN A/C>	3,977,273	1.40%
15	HUNTER CAPITAL ADVISORS P/L	3,750,000	1.32%
16	MR DANIEL MORRIS KENNEDY <DANIEL MORRIS KENNEDY A/C>	3,750,000	1.32%
17	MISHTALEM PTY LTD	3,750,000	1.32%
18	MR RICKY STEVEN NEUMANN	3,750,000	1.32%
19	FIRST OAK CAPITAL PTY LTD	3,409,091	1.20%
20	HIRSCH FINANCIAL PTY LTD	3,409,091	1.20%
Total		182,205,868	
Grand Total		284,981,422	

--ENDS--

This announcement is authorised for release to the market by the Company Secretary of Invion Limited.



Investor and Media enquiries:

Thian Chew (Chairman)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

T: +61 409 341 613

E: brendon@vantagepointpartners.com.au

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.